XLV250103C149000
- 0.08
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Unpacking the Latest Options Trading Trends in Merck & Co
Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Merck & Compnay and OPKO Health Shares Are Trading Higher After the Companies Announced a License and Collaboration Agreement to Develop an Epstein-Barr Virus Vaccine.
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Bird Flu Claims First U.S. Life in Louisiana
Danaher Analyst Ratings
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Sentiment Has Been Shifting Away From Small Caps and Cyclicals
Wells Fargo Spotlights 31 Names It Believes 'Offer Above-average Growth Potential'
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development